In agallamh le déanaí, d'inis an Dr. Afsaneh Barzi, ollamh cúnta le leigheas cliniciúil in Ionad Cuimsitheach Ailse Norris Ollscoil Southern California, duit faoi teiripí aidiúvacha nua atá ann cheana agus atá ag teacht chun cinn d'othair a bhfuil ailse paincréasach neamh-mheatastatach orthu.
Tugtar Gemcitabine d’othair a bhfuil ailse pancreatach orthu mar ghnáthchleachtas chun freagairt a mheas. Dúirt Barzi, áfach, go raibh freagra an othair ar gemcitabine an-lag agus nach raibh go leor othar in ann dul faoi obráid. Rinne triail LAPACT imscrúdú ar theiripe teaglaim gemcitabine agus nab-paclitaxel (Abraxane). Taispeánann tástálacha go bhfreagraíonn 36% d’othair ailse pancreatic do chóireáil, agus is féidir le thart ar 15% d’othair ailse pancreatic cóireáil mháinliachta a fháil.
In addition, a meta-analysis of the FOLFIRINOX study of patients with locally advanced pancreatic cancer showed that approximately 28% of pancreatic cancer patients were able to undergo surgery. Barzi explained that as chemotherapy becomes more effective, the likelihood of resection increases. Therefore, the patient’s resection should be evaluated accordingly. Barzi concluded that although most patients may still not be eligible for surgery, it is still worth evaluating patients to find patients who can undergo surgery after neoadjuvant therapy.